Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01861002 | A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML | completed | Phase 1 | 15 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Jun 9, 2021 | clinicaltrials |
| NCT02046291 | Safety of Romiplostim (Nplate®) Following UCBT | completed | Phase 1 | 21 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 8, 2021 |
| NCT03259529 | Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL(BeGeRN) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT02609230 | A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma | completed | Phase 1 | 33 | Fox Chase Cancer CenterOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT03239392 | A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL | completed | Phase 1 / Phase 2 | 50 | Bioniz TherapeuticsINDUSTRY | 1 | May 25, 2021 | clinicaltrials |
| NCT03885947 | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | completed | Phase 1 | 7 | Alla KeyznerOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | completed | Phase 1 | 183 | ADC Therapeutics S.A.INDUSTRY | 3 | May 19, 2021 | clinicaltrials |
| NCT03498430 | Copanlisib Chinese PK Study | completed | Phase 1 | 13 | BayerINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT03892421 | Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 22 | La Raza Medical CenterOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT02485535 | Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant | completed | Phase 1 | 12 | University of ChicagoOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT00792467 | Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 24 | ItalfarmacoINDUSTRY | 1 | May 11, 2021 | clinicaltrials |
| NCT02129582 | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT02841033 | Daratumumab for the Treatment of Patients With AL Amyloidosis | completed | Phase 1 / Phase 2 | 22 | Boston Medical CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT01742988 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | completed | Phase 1 | 106 | Curis, Inc.INDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT03466320 | DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2(DEPLETHINK) | completed | Phase 1 / Phase 2 | 21 | Celyad Oncology SAINDUSTRY | 2 | May 4, 2021 | clinicaltrials |
| NCT00981708 | Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) | completed | Phase 1 / Phase 2 | 37 | University of AthensOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03212937 | Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma | completed | Phase 1 | 11 | National Cancer Centre, SingaporeOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT00866307 | Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) | completed | Phase 1 | 104 | Children's Oncology GroupNETWORK | 3 | Apr 27, 2021 | clinicaltrials |
| NCT02187133 | Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 | 10 | University of California, San FranciscoOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02323178 | A Study of Eltrombopag in Patients With CMML and Thrombocytopenia | completed | Phase 1 / Phase 2 | 30 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT02545907 | A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis(CATALYST) | completed | Phase 1 / Phase 2 | 10 | University College, LondonOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT00450944 | Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 | 10 | Albert Einstein College of MedicineOTHER | 1 | Apr 14, 2021 | clinicaltrials |
| NCT00858234 | Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) | completed | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 9, 2021 | clinicaltrials |
| NCT02431208 | A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) | completed | Phase 1 | 85 | Hoffmann-La RocheINDUSTRY | 1 | Apr 2, 2021 | clinicaltrials |
| NCT02528682 | MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT(PSCT19) | completed | Phase 1 / Phase 2 | 10 | Radboud University Medical CenterOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT03790072 | Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 10 | TC BiopharmINDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02805075 | Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 15 | Stanford UniversityOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03003039 | A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 85 | Nanjing Yoko Biomedical Co., Ltd.INDUSTRY | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03076437 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | completed | Phase 1 / Phase 2 | 28 | Shenzhen Institute for Innovation and Translational MedicineOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT01659255 | Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL | completed | Phase 1 | 90 | Gilead SciencesINDUSTRY | 2 | Mar 16, 2021 | clinicaltrials |
| NCT03415399 | Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma | completed | Phase 1 | 4 | Eureka Therapeutics Inc.INDUSTRY | 1 | Mar 16, 2021 | clinicaltrials |
| NCT03081780 | Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML | completed | Phase 1 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT01207921 | Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma | completed | Phase 1 | 28 | Washington University School of MedicineOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT01440920 | A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients | completed | Phase 1 | 9 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 8, 2021 | clinicaltrials |
| NCT02293993 | Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia | completed | Phase 1 | 21 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 5, 2021 | clinicaltrials |
| NCT00620633 | Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | completed | Phase 1 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT01475370 | Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001) | completed | Phase 1 | 18 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 2, 2021 | clinicaltrials |
| NCT00306202 | Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia | completed | Phase 1 | 63 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 26, 2021 | clinicaltrials |
| NCT03381768 | Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma | completed | Phase 1 | 8 | Lars Møller PedersenOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT01169532 | Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 16 | Fox Chase Cancer CenterOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02059239 | Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | completed | Phase 1 / Phase 2 | 34 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02740270 | Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | completed | Phase 1 | 92 | Novartis PharmaceuticalsINDUSTRY | 6 | Feb 21, 2021 | clinicaltrials |
| NCT03489369 | Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | completed | Phase 1 | 15 | Symphogen A/SINDUSTRY | 2 | Feb 18, 2021 | clinicaltrials |
| NCT01260545 | Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 14 | Janssen Research & Development, LLCINDUSTRY | 1 | Feb 16, 2021 | clinicaltrials |
| NCT03197714 | Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia | completed | Phase 1 | 9 | Hospital Universitario 12 de OctubreOTHER | 1 | Feb 15, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Jun 9, 2021source: clinicaltrials